Varian Medical instead of Siemens: the oncological center, largest in Hungary, updates the equipment
| Customers: National Institute of oncology in Budapest Pharmaceutics, medicine, health care Contractors: Varian Medical Systems Project date: 2017/03
|
In March, 2017 the National Institute of oncology in Budapest which is the center of treatment of cancer diseases, largest in Hungary, announced purchase of medical equipment and software at the Varian Medical Systems company specializing in radiotherapeutic solutions.
The National Institute of oncology upgrades the therapeutic equipment using the Varian Medical linear particle accelerators. In particular, instead of an obsolete equipment of Siemens two modern VitalBeam systems will be installed, and will install the Varian Unique device instead of the old unit with radioactive cobalt. The new systems are going to be implemented in work during 2017. The financial component of the transaction does not reveal.
 | These modern systems allow us to provide to our patients better treatment — doctor Csaba Polgar heading radiotherapeutic office of National Institute of oncology in Budapest says. — We set Varian TrueBeam three years ago, and now we will be able to take advantage of integration of new devices with this system and also an opportunity if necessary to transfer patients from one installation on another. |  |
The medical center also buys from Varian a complete set of the software for management of oncological information of ARIA which completely will replace the deployed Siemens Lantis system.
It is noted that VitalBeam represents the economic solution for high-quality and high-performance radiation therapy allowing clients to expand the clinical opportunities and over time to service bigger number of patients using modern technologies of treatment.
Unique is positioned as the only low-energy radiotherapeutic system in the world with visualization control and functions of holding procedures RapidArc. As well as other Varian linear particle accelerators, this solution are made by treatment of oncological diseases more available to patients worldwide, the press release says.[1]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |